Combination of Deauville score and quantitative positron emission tomography parameters as a predictive tool of anti-CD19 chimeric antigen receptor T-cell efficacy.

"CONFLICTS OF INTEREST Giovanni Argiroffi reports consulting fees from Fondazione IRCCS Istituto Nazionale Tumori. Filippo Bagnoli reports consulting fees from Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico. Annalisa Chiappella reports consulting fees from AstraZeneca, Celgene, Clinigen, Gilead Sciences, Incyte, Janssen Biotech, Novartis, Roche, Secura Bio, and Takeda Oncology. Paolo Corradini reports consulting fees from Gilead Sciences and Novartis. Anna Guidetti reports consulting fees from Gilead Sciences and GlaxoSmithKline and travel fees from F. Hoffmann‐La Roche, Janssen Biotech, and Novartis. Martina Pennisi reports consulting fees from Bristol‐Myers Squibb, Gilead Sciences, and Nektar Therapeutics and travel fees from Roche s.p.a. The other authors made no disclosures."

"Authors received no financial support for the research, authorship, and/or publication of this article."